Our study confirms and builds on the findings of Minagar and colleagues (Minagar et al., 2003) who demonstrated that serum from patients with MS reduces VE-cadherin and occludin levels in endothelial cells in vitro. This evidence concerns the gene OCLN and myeloid sarcoma.